Genen­ta is at­tempt­ing a rare biotech leap from Mi­lan to Wall Street

Pier­lui­gi Parac­chi, CEO and one of the trio of lead­ers run­ning gene ther­a­py biotech Genen­ta, has fre­quent­ly lament­ed the ab­sence of Ital­ian biotechs on Nas­daq. And now, he’s tak­ing his Mi­lan-based com­pa­ny and jump­ing out in front of what he hopes some­day will be a pack of biotechs go­ing pub­lic in the US.

The Ital­ian biotech has been busy re­cent­ly with Phase I/II tri­als on their in­ves­ti­ga­tion­al glioblas­toma can­di­date Tem­fer­on — and it’s look­ing to ex­pand with an IPO. The six-year-old small biotech, found­ed out of the renowned San Raf­faele Hos­pi­tal in Mi­lan — led by a biotech ex­ec­u­tive, a not­ed aca­d­e­m­ic and a physi­cian — filed a Form F-1 with the SEC on Tues­day, pen­cil­ing in a planned raise of $35 mil­lion, though that’s been known to change in the lead­up to the flip on­to Wall Street.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER